{"id":13220,"date":"2010-07-16T10:45:00","date_gmt":"2010-07-16T08:45:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/glaxo-prevede-costi-legali-record\/"},"modified":"2010-07-16T10:45:00","modified_gmt":"2010-07-16T08:45:00","slug":"glaxo-prevede-costi-legali-record","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/glaxo-prevede-costi-legali-record\/","title":{"rendered":"Glaxo expects record legal costs"},"content":{"rendered":"<p><a id=\"apf5\" href=\"http:\/\/www.google.it\/imgres?imgurl=http:\/\/ceoworld.biz\/ceo\/wp-content\/uploads\/2009\/10\/glaxo_smithkline.jpg&amp;imgrefurl=http:\/\/ceoworld.biz\/ceo\/tag\/roche&amp;usg=__I__dd8dSrc9W_ppPeQ0QtbORnHM=&amp;h=260&amp;w=400&amp;sz=52&amp;hl=it&amp;start=6&amp;sig2=DsmgTL5nFXNFIFE28qnV_A&amp;um=1&amp;itbs=1&amp;tbnid=feeRbxFhcrCOWM:&amp;tbnh=81&amp;tbnw=124&amp;prev=\/images%3Fq%3Dglaxo%26um%3D1%26hl%3Dit%26sa%3DG%26gbv%3D2%26tbs%3Disch:1&amp;ei=1yxATOu_Cs-TjAfl7PQQ\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" style=\"border-bottom: #ccc 1px solid; border-left: #ccc 1px solid; padding-bottom: 1px; padding-left: 1px; width: 226px; padding-right: 1px; height: 159px; vertical-align: bottom; border-top: #ccc 1px solid; border-right: #ccc 1px solid; padding-top: 1px\" id=\"ipffeeRbxFhcrCOWM:\" alt=\"\" width=\"124\" height=\"81\" src=\"http:\/\/t1.gstatic.com\/images?q=tbn:feeRbxFhcrCOWM:http:\/\/ceoworld.biz\/ceo\/wp-content\/uploads\/2009\/10\/glaxo_smithkline.jpg\" \/><\/a>&nbsp;<em>GlaxoSmithKline Plc&#039;s<\/em><\/p>\n<p style=\"margin: 0cm 0cm 0pt\" class=\"MsoNormal\"><font size=\"3\"><font face=\"Calibri\">GlaxoSmithKline expects to report record \u00a31.57 billion in legal fees in the second quarter. The Bloomberg agency writes that it cites a document from the pharmaceutical group with the latest updates on a series of disputes, including those for the drug Avandia, held responsible for heart attacks, and for the antidepressant Paxil.<\/p>\n<p><\/font><\/font><\/p>\n<p style=\"margin: 0cm 0cm 0pt\" class=\"MsoNormal\"><font size=\"3\"><font face=\"Calibri\"><em>Il Gazzettino \u2013 16 July 2010 p. 17&nbsp;&nbsp; <a id=\"thumbnail\" href=\"http:\/\/www.quelveneto.it\/quelveneto\/wp-content\/uploads\/2008\/08\/il-gazzettino-online.jpg\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" style=\"border-bottom: 1px solid; border-left: 1px solid; margin: 10px 10px 0px; float: left; border-top: 1px solid; border-right: 1px solid\" alt=\"Mostra immagine a dimensione intera\" width=\"90\" height=\"80\" src=\"http:\/\/t1.gstatic.com\/images?q=tbn:fVuZcbnbX34DjM:http:\/\/www.quelveneto.it\/quelveneto\/wp-content\/uploads\/2008\/08\/il-gazzettino-online.jpg\" \/><\/a><\/p>\n<p><\/em><\/font><\/font><\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp;GlaxoSmithKline Plc&#8217;s GlaxoSmithKline prevede di riportare nel secondo trimestre oneri legali record per 1,57 miliardi di sterline. Lo scrive l&rsquo;agenzia Bloomberg che cita un documento del gruppo farmaceutico con gli ultimi aggiornamenti su una serie di contenziosi, tra cui quelli per il farmaco Avandia, ritenuto responsabile di attacchi cardiaci, e per l&rsquo;antidepressivo Paxil. Il Gazzettino &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13220","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13220"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13220\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}